Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOR103 in patients with active rheumatoid arthritis
2007-006129-29Phase 2Completed
- Sponsor
- MorphoSys AG
- Start
- Jun 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing MOR103 with Placebo (2 arms). Primary endpoint: Safety and tolerability of MOR103. Started Jun 2009; status: completed.
02
Drugs
otilimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2007-006129-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006129-29.